Phase 1b Study of DISC-3405 for Sickle Cell Disease
This study is testing a new medication called DISC-3405 for people with Sickle Cell Disease (SCD). DISC-3405 is given as a shot under the skin. Researchers want to see how safe DISC-3405 is and how well your body tolerates it. They are also looking at how the drug moves through your body and what effects it has. You may be able to join if you are 18 years or older, have SCD (HbSC or HbSS type), and have experienced certain SCD-related problems like pain crises (VOCs), eye problems, or silent strokes. The study aims to understand the safety and tolerability of DISC-3405 over about 36 weeks. The current recruitment status is unclear.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It will involve about 24 participants and will test up to three different dose levels of DISC-3405.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal of the study is to measure safety and tolerability for up to 36 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
At a glance
Conditions
Where it's being run
8 sites across 7 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and tolerability of DISC-3405 administration in participants with SCDUp to 36 weeks
Proportion of participants with treatment-emergent adverse events (TEAEs), changes in vital signs, changes in physical examinations, changes in electrocardiograms (ECGs), and changes in clinical laboratory results